CL2017000379A1 - Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll. 7 (tlr7) - Google Patents

Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll. 7 (tlr7)

Info

Publication number
CL2017000379A1
CL2017000379A1 CL2017000379A CL2017000379A CL2017000379A1 CL 2017000379 A1 CL2017000379 A1 CL 2017000379A1 CL 2017000379 A CL2017000379 A CL 2017000379A CL 2017000379 A CL2017000379 A CL 2017000379A CL 2017000379 A1 CL2017000379 A1 CL 2017000379A1
Authority
CL
Chile
Prior art keywords
tlr7
compounds used
receptor agonists
toll receptor
pyrrolopyrimidine compounds
Prior art date
Application number
CL2017000379A
Other languages
English (en)
Inventor
Zhaozhong Ding
Hao Wu
Fei Sun
Lifang Wu
Ling Yang
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201410405136.0A external-priority patent/CN105367576A/zh
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CL2017000379A1 publication Critical patent/CL2017000379A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

<p>La presente invención se refiere a un compuesto de pirrolopirimidina como agonista de TLR7, y particularmente se refiere a un compuesto de la fórmula (l) o una sal farmacéuticamente aceptable del mismo, un procedimiento de fabricación del mismo, una composición farmacéutica que contiene dicho compuesto, y su uso en la fabricación de un medicamento contra una infección viral.</p>
CL2017000379A 2014-08-15 2017-02-14 Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll. 7 (tlr7) CL2017000379A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410405136.0A CN105367576A (zh) 2014-08-15 2014-08-15 作为tlr7激动剂的吡咯并嘧啶化合物
CN201510392499 2015-07-06

Publications (1)

Publication Number Publication Date
CL2017000379A1 true CL2017000379A1 (es) 2018-04-27

Family

ID=55303885

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000379A CL2017000379A1 (es) 2014-08-15 2017-02-14 Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll. 7 (tlr7)

Country Status (26)

Country Link
US (2) US9962388B2 (es)
EP (1) EP3190113B1 (es)
JP (2) JP6328341B2 (es)
KR (2) KR102215609B1 (es)
CN (4) CN110938076B (es)
AU (3) AU2015303558B2 (es)
BR (1) BR112017002811B1 (es)
CA (1) CA2958097C (es)
CL (1) CL2017000379A1 (es)
DK (1) DK3190113T3 (es)
EA (1) EA032824B1 (es)
ES (1) ES2875313T3 (es)
HR (1) HRP20210927T1 (es)
HU (1) HUE054672T2 (es)
IL (2) IL250586B (es)
LT (1) LT3190113T (es)
MX (1) MX2017002028A (es)
MY (1) MY190026A (es)
PH (2) PH12017500281A1 (es)
PL (1) PL3190113T3 (es)
PT (1) PT3190113T (es)
SG (2) SG10201809918RA (es)
SI (1) SI3190113T1 (es)
UA (1) UA117634C2 (es)
WO (1) WO2016023511A1 (es)
ZA (1) ZA201803736B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10442811B2 (en) 2016-02-05 2019-10-15 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Crystal form A of 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-D] pyrimidin-4-amine, preparation process and use thereof

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3160513B1 (en) 2014-06-30 2020-02-12 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
UA117634C2 (uk) * 2014-08-15 2018-08-27 Чиа Тай Тяньцін Фармасьютикал Ґруп Ко., Лтд. Піролопіримідинові сполуки, що використовуються як агоніст tlr7
MY182353A (en) 2015-05-08 2021-01-20 Hoffmann La Roche Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
BR112018008880B1 (pt) * 2015-11-05 2023-01-17 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 7-(tiazol-5-il) pirrolopirimidina, seu uso, e composição farmacêutica
CN107043378A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体
CN107043377A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的三氟乙酸盐、晶型b及其制备方法、药物组合物和用途
CN107043380A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
CA3026074A1 (en) 2016-06-01 2017-12-07 M3 Biotechnology, Inc. N-hexanoic-l-tyrosine-l-isoleucine-(6)-aminohexanoic amide compounds and their use to treat neurodegenerative diseases
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
CA3034148A1 (en) 2016-08-29 2018-03-08 F. Hoffmann-La Roche Ag 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
BR112019004597A2 (pt) 2016-09-09 2019-06-11 Novartis Ag compostos e composições como inibidores de receptores endossomais do tipo toll
BR112019004560A2 (pt) 2016-09-13 2019-07-02 Hoffmann La Roche tratamento combinado com agonista de tlr7 e um inibidor de formação de capsídeo de hbv
IL265921B1 (en) 2016-10-14 2024-01-01 Prec Biosciences Inc Transgenic meganonucleases specific for recognition sequences in the hepatitis B virus genome
WO2018078149A1 (en) * 2016-10-31 2018-05-03 F. Hoffmann-La Roche Ag Novel cyclicsulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
JP6932394B2 (ja) 2016-11-11 2021-09-08 ヘポ ファーマスーティカル カンパニー リミテッド 含窒素複素環化合物、製造方法、中間体、医薬組成物及び応用
AU2017366621B2 (en) * 2016-11-28 2021-07-29 Jiangsu Hengrui Medicine Co., Ltd. Pyrazolo-heteroaryl derivative, preparation method and medical use thereof
CN110177793B (zh) * 2017-05-18 2021-12-21 江苏恒瑞医药股份有限公司 杂芳基并吡唑类衍生物、其制备方法及其在医药上的应用
US10487084B2 (en) 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
US10508115B2 (en) 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
US10457681B2 (en) 2017-08-16 2019-10-29 Bristol_Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
US10472361B2 (en) 2017-08-16 2019-11-12 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
US10494370B2 (en) 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
EP3710440B1 (en) 2017-11-14 2023-04-05 Bristol-Myers Squibb Company Substituted indole compounds
CA3085817A1 (en) 2017-12-18 2019-06-27 Bristol-Myers Squibb Company 4-azaindole compounds
EA202091483A1 (ru) 2017-12-19 2020-10-28 Бристол-Маерс Сквибб Компани Амидзамещенные индольные соединения, пригодные в качестве ингибиторов tlr
WO2019126113A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Substituted indole compounds useful as tlr inhibitors
EP3728253B1 (en) 2017-12-19 2024-03-27 Bristol-Myers Squibb Company 6-azaindole compounds
SG11202005733QA (en) * 2017-12-20 2020-07-29 Bristol Myers Squibb Co Diazaindole compounds
US10966999B2 (en) 2017-12-20 2021-04-06 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
EA202091479A1 (ru) 2017-12-20 2020-11-24 Бристол-Маерс Сквибб Компани Арил- и гетероарилзамещенные индольные соединения
AU2018392212B9 (en) 2017-12-20 2021-03-18 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
CN111491929B (zh) 2017-12-20 2023-11-28 百时美施贵宝公司 可用作tlr抑制剂的氨基吲哚化合物
WO2019155042A1 (en) 2018-02-12 2019-08-15 F. Hoffmann-La Roche Ag Novel sulfone compounds and derivatives for the treatment and prophylaxis of virus infection
EP3759109B1 (en) 2018-02-26 2023-08-30 Gilead Sciences, Inc. Substituted pyrrolizine compounds as hbv replication inhibitors
US10870691B2 (en) 2018-04-05 2020-12-22 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis B virus protein X
WO2019193543A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
US11485741B2 (en) 2018-04-24 2022-11-01 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (TLR7) agonists
TW202014193A (zh) 2018-05-03 2020-04-16 捷克科學院有機化學與生物化學研究所 包含碳環核苷酸之2’3’－環二核苷酸
AU2019272478A1 (en) * 2018-05-25 2020-12-17 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. TLR7 agonist and pharmaceutical combination thereof for treating lung cancer
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
EP3865483A4 (en) * 2018-10-12 2022-06-08 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. TLR7 AGONIST FOR THE TREATMENT OF COLORECTAL CANCER AND PHARMACEUTICAL COMBINATION THEREOF
EP3873608A1 (en) 2018-10-31 2021-09-08 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
CA3117556A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
WO2020162705A1 (ko) 2019-02-08 2020-08-13 성균관대학교산학협력단 톨-유사 수용체 7 또는 8 작용자와 콜레스테롤의 결합체 및 그 용도
CN113543851A (zh) 2019-03-07 2021-10-22 捷克共和国有机化学与生物化学研究所 2’3’-环二核苷酸及其前药
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
JP7350872B2 (ja) 2019-03-07 2023-09-26 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． ３’３’－環状ジヌクレオチドおよびそのプロドラッグ
US20220249488A1 (en) 2019-03-15 2022-08-11 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Toll-like receptor agonists for use in the treatment of hepatitis b
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
CA3137202A1 (en) 2019-04-23 2020-10-29 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Solid pharmaceutical composition comprising tlr7 agonist
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
EP4008720A4 (en) 2019-08-02 2023-08-02 BeiGene, Ltd. IMIDAZO [2,1-F][1,2,4] TRIAZINE-4-AMINE DERIVATIVES AS A TLR8 AGONIST
WO2021034804A1 (en) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
WO2021058021A1 (zh) 2019-09-29 2021-04-01 正大天晴药业集团股份有限公司 包含tlr7激动剂的药物组合
CN114555799A (zh) 2019-09-30 2022-05-27 吉利德科学公司 Hbv疫苗和治疗hbv的方法
EP4069729A1 (en) 2019-12-06 2022-10-12 Precision BioSciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
CN115135654A (zh) 2020-01-27 2022-09-30 百时美施贵宝公司 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
WO2021154668A1 (en) 2020-01-27 2021-08-05 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
CN115210236A (zh) 2020-01-27 2022-10-18 百时美施贵宝公司 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
WO2021154662A1 (en) 2020-01-27 2021-08-05 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
EP4097100A1 (en) 2020-01-27 2022-12-07 Bristol-Myers Squibb Company 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists
US20230127326A1 (en) 2020-01-27 2023-04-27 Bristol-Myers Squibb Company C3-SUBSTITUTED 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
EP4097104A1 (en) 2020-01-27 2022-12-07 Bristol-Myers Squibb Company 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists
WO2021154669A1 (en) 2020-01-27 2021-08-05 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
CN115135655A (zh) 2020-01-27 2022-09-30 百时美施贵宝公司 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
CA3170551A1 (en) 2020-03-02 2021-09-10 Yong Taik Lim Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof
EP4121437A1 (en) 2020-03-20 2023-01-25 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
KR20230035031A (ko) 2020-06-05 2023-03-10 킨네이트 바이오파마 인크. 섬유아세포 성장 인자 수용체 키나아제의 억제제
JP2023536954A (ja) 2020-08-04 2023-08-30 プロジェニア インコーポレイテッド 活性化部位が一時的に不活性化したトール様受容体７または８作用薬と機能性薬物の結合体およびその用途
EP4194008A1 (en) 2020-08-04 2023-06-14 Progeneer Inc. Kinetically acting adjuvant ensemble
EP4194006A1 (en) 2020-08-04 2023-06-14 Progeneer Inc. Mrna vaccine comprising adjuvant capable of kinetic control
CN115119508A (zh) * 2021-01-20 2022-09-27 上海维申医药有限公司 大环tlr7激动剂、其制备方法、药物组合物及其用途
WO2022206752A1 (zh) 2021-03-29 2022-10-06 正大天晴药业集团股份有限公司 Toll样受体7激动剂和抗PD-L1抗体的药物联合
WO2022241134A1 (en) 2021-05-13 2022-11-17 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
CN117377671A (zh) 2021-06-23 2024-01-09 吉利德科学公司 二酰基甘油激酶调节化合物
US11932634B2 (en) 2021-06-23 2024-03-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
EP4359415A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN114409654A (zh) * 2021-12-30 2022-04-29 安徽普利药业有限公司 一种btk抑制剂的中间体合成方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2232871T3 (es) 1996-07-03 2005-06-01 Sumitomo Pharmaceuticals Company, Limited Nuevos derivados de purina.
US6329381B1 (en) 1997-11-28 2001-12-11 Sumitomo Pharmaceuticals Company, Limited Heterocyclic compounds
EP1931352B1 (en) * 2005-08-22 2016-04-13 The Regents of The University of California Tlr agonists
PL2125007T3 (pl) * 2007-02-07 2014-07-31 Univ California Koniugaty syntetycznych agonistów TLR i ich zastosowania
TWI434849B (zh) 2007-06-29 2014-04-21 Gilead Sciences Inc 類鐸（Ｔｏｌｌ－ｌｉｋｅ）受體７之調節劑
ATE501136T1 (de) 2007-08-03 2011-03-15 Pfizer Ltd Imidazopyridinone
KR101787309B1 (ko) 2008-12-09 2017-10-18 길리애드 사이언시즈, 인코포레이티드 톨-유사 수용체의 조절제
DE102011008352A1 (de) * 2011-01-12 2012-07-12 Merck Patent Gmbh 5-([1,2,3]Triazol-4-yl)-7H-pyrrolo-[2,3-d]pyrimidinderivate
US9139590B2 (en) * 2011-02-04 2015-09-22 Duquesne University Of The Holy Spirit Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient
EP2674170B1 (en) * 2012-06-15 2014-11-19 Invivogen Novel compositions of TLR7 and/or TLR8 agonists conjugated to lipids
HUE037064T2 (hu) * 2012-10-10 2018-08-28 Janssen Sciences Ireland Uc Pirrolo[3,2-d]-pirimidin származékok vírusos fertõzések és egyéb betegségek kezelésére
US9550785B2 (en) * 2012-11-20 2017-01-24 Glaxosmithkline Llc Pyrrolopyrimidines as therapeutic agents for the treatment of diseases
ES2625023T3 (es) * 2012-11-20 2017-07-18 Glaxosmithkline Llc Compuestos novedosos
HUE13857477T2 (hu) * 2012-11-20 2018-05-28 Glaxosmithkline Llc Új vegyületek
CA2938476A1 (en) 2014-02-20 2015-08-27 Glaxosmithkline Intellectual Property (No.2) Limited Pyrrolo[3,2-d]pyrimidine derivatives as inducers of human interferon
NZ724878A (en) 2014-05-01 2019-03-29 Novartis Ag Compounds and compositions as toll-like receptor 7 agonists
EA030603B1 (ru) 2014-05-01 2018-08-31 Новартис Аг СОЕДИНЕНИЯ И КОМПОЗИЦИИ В КАЧЕСТВЕ АГОНИСТОВ Toll-ПОДОБНОГО РЕЦЕПТОРА 7
UA117634C2 (uk) * 2014-08-15 2018-08-27 Чиа Тай Тяньцін Фармасьютикал Ґруп Ко., Лтд. Піролопіримідинові сполуки, що використовуються як агоніст tlr7
CN105732635A (zh) 2014-12-29 2016-07-06 南京明德新药研发股份有限公司 一类Toll样受体7激动剂

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10442811B2 (en) 2016-02-05 2019-10-15 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Crystal form A of 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-D] pyrimidin-4-amine, preparation process and use thereof
US10947245B2 (en) 2016-02-05 2021-03-16 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Crystal form A of 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine for inhibiting toll-like receptor activity

Also Published As

Publication number Publication date
ES2875313T3 (es) 2021-11-10
SG11201701169XA (en) 2017-03-30
BR112017002811B1 (pt) 2022-09-06
CA2958097A1 (en) 2016-02-18
AU2018236899B2 (en) 2019-07-25
US9962388B2 (en) 2018-05-08
NZ761639A (en) 2023-08-25
AU2019253788A1 (en) 2019-11-14
CN110759916B (zh) 2021-02-19
JP6328341B2 (ja) 2018-05-23
DK3190113T3 (da) 2021-06-07
CN106661034A (zh) 2017-05-10
CA2958097C (en) 2019-05-14
AU2015303558A1 (en) 2017-03-30
EA201790389A1 (ru) 2017-06-30
PH12020551089A1 (en) 2021-05-10
AU2019253788C1 (en) 2020-09-17
CN110759916A (zh) 2020-02-07
JP6639551B2 (ja) 2020-02-05
BR112017002811A2 (pt) 2017-12-19
CN110938076B (zh) 2021-08-10
KR20170041913A (ko) 2017-04-17
CN110938076A (zh) 2020-03-31
SI3190113T1 (sl) 2021-09-30
IL250586A0 (en) 2017-04-30
MX2017002028A (es) 2017-08-14
UA117634C2 (uk) 2018-08-27
KR102215609B1 (ko) 2021-02-15
HRP20210927T1 (hr) 2021-09-03
JP2017524037A (ja) 2017-08-24
US20180303832A1 (en) 2018-10-25
CN112898308A (zh) 2021-06-04
US10555949B2 (en) 2020-02-11
US20170273983A1 (en) 2017-09-28
LT3190113T (lt) 2021-08-25
PH12017500281B1 (en) 2017-07-03
WO2016023511A1 (zh) 2016-02-18
EP3190113A1 (en) 2017-07-12
ZA201803736B (en) 2020-08-26
PL3190113T3 (pl) 2021-10-25
NZ730011A (en) 2023-08-25
PH12017500281A1 (en) 2017-07-03
AU2019253788B2 (en) 2020-05-28
EA032824B1 (ru) 2019-07-31
EP3190113B1 (en) 2021-05-19
AU2015303558B2 (en) 2018-07-12
EP3190113A4 (en) 2018-01-24
IL276908A (en) 2020-10-29
IL250586B (en) 2020-09-30
KR20190098277A (ko) 2019-08-21
JP2018123160A (ja) 2018-08-09
MY190026A (en) 2022-03-22
PT3190113T (pt) 2021-06-17
HUE054672T2 (hu) 2021-09-28
CN106661034B (zh) 2019-11-29
AU2018236899A1 (en) 2018-10-18
SG10201809918RA (en) 2018-12-28

Similar Documents

Publication Publication Date Title
CL2017000379A1 (es) Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll. 7 (tlr7)
CL2017001426A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
DOP2019000201A (es) Compuestos inhibidores del vih
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
BR112017010354B8 (pt) Compostos de triazolopirimidina, seu uso, e composição farmacêutica
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CU20150096A7 (es) Compuestos de amida y composición farmacéutica para el tratamiento de vih
CR20130560A (es) Compuestos de bezotiazol y su uso farmacéutico
EA201791256A1 (ru) Производные хиназолина, применяемые для лечения вич
CU20170009A7 (es) 2-(morfolin-4-il)-1,7-naftiridinas útiles en el tratamiento o la profilaxis de enfermedades hiperproliferativas
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
BR112017013491A2 (pt) compostos de pirimidina fundida para o tratamento de hiv
PE20160605A1 (es) Formulaciones de inhibidores de la syk
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
GT201500053A (es) Composicion farmaceutica recubierta que contiene regorafenib
NI201800071A (es) Compuestos de isoindol
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
CL2017001483A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
PH12018500378A1 (en) Novel annelated phenoxyacetamides
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
CR20160016A (es) Pirazolpiridinas sustituidas
CL2015002466A1 (es) Formulaciones de compuestos orgánicos
DOP2019000021A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana